Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.

Publication ,  Journal Article
Welsh, RC; Roe, MT; Steg, PG; James, S; Povsic, TJ; Bode, C; Gibson, CM; Ohman, EM
Published in: Am Heart J
November 2016

Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards. Indeed it is unclear how regulatory agencies would define the optimal dose or duration of aspirin therapy if assessed in the current era. Subsequent clinical investigation has focused on the addition of antithrombotic agents on top of baseline aspirin therapy in the acute and chronic setting to reduce patient's risk of further ischemic events, at the cost of increased bleeding complications. The current armamentarium of potent and predictable antiplatelet and antithrombotic agents has ushered in a new era where clinicians and scientists are contemplating withdrawal of previously established agents to minimize bleeding risk while sustaining efficacy; indeed, subtraction may lead to the next advance in the treatment of acute and chronic ischemic vascular disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2016

Volume

181

Start / End Page

92 / 100

Location

United States

Related Subject Headings

  • Ticlopidine
  • Ticagrelor
  • Secondary Prevention
  • Purinergic P2Y Receptor Antagonists
  • Prasugrel Hydrochloride
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Humans
  • History, Ancient
  • History, 21st Century
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Welsh, R. C., Roe, M. T., Steg, P. G., James, S., Povsic, T. J., Bode, C., … Ohman, E. M. (2016). A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J, 181, 92–100. https://doi.org/10.1016/j.ahj.2016.08.008
Welsh, Robert C., Matthew T. Roe, Philippe Gabriel Steg, Stefan James, Thomas J. Povsic, Christoph Bode, Charles Michael Gibson, and Erik Magnus Ohman. “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.Am Heart J 181 (November 2016): 92–100. https://doi.org/10.1016/j.ahj.2016.08.008.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, et al. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J. 2016 Nov;181:92–100.
Welsh, Robert C., et al. “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.Am Heart J, vol. 181, Nov. 2016, pp. 92–100. Pubmed, doi:10.1016/j.ahj.2016.08.008.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J. 2016 Nov;181:92–100.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2016

Volume

181

Start / End Page

92 / 100

Location

United States

Related Subject Headings

  • Ticlopidine
  • Ticagrelor
  • Secondary Prevention
  • Purinergic P2Y Receptor Antagonists
  • Prasugrel Hydrochloride
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Humans
  • History, Ancient
  • History, 21st Century